Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pacritinib

Known as: Oral JAK2 Inhibitor SB1518 
An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Importance Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia is… Expand
  • figure 1
  • figure 2
Review
2017
Review
2017
BACKGROUND Available therapies for myelofibrosis can exacerbate cytopenias and are not indicated for patients with severe… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2016
2016
Pacritinib, potent inhibitor of Janus kinase 2 (JAK2), JAK2V617F, and fms-like receptor tyrosine kinase 3, is in Phase III… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
2016
2016
BackgroundPacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R. This… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 4
2016
2016
Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is… Expand
2016
2016
Background: PAC is an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R that has demonstrated significant… Expand
Highly Cited
2015
Highly Cited
2015
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1… Expand
Highly Cited
2012
Highly Cited
2012
Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2011
Highly Cited
2011
FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2011
Highly Cited
2011
Abstract 282 Background: The JAK2V617F mutation has been linked to the pathogenesis of myeloproliferative neoplasia. Pacritinib… Expand